Occupational Epoxy Allergy in 209 Clinically Confirmed Cases
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work or activity setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
This review asks a narrow question about workplace or activity-related skin evidence while preserving the paper’s actual population, denominator, design and timepoint.
What did researchers study?
| Study element | Reported detail |
|---|---|
| Population | 209 patients with occupational contact allergy to components of epoxy resin systems |
| Design | Retrospective clinical test-file analysis |
| Timepoint | January 1991 through June 2014 |
| Key result | Painters were the largest group (41); 82% reacted to DGEBA resin. Hands/upper extremities were affected in 69% and facial symptoms in 60%. |
What the numbers do—and do not—show
Painters were the largest group (41); 82% reacted to DGEBA resin. Hands/upper extremities were affected in 69% and facial symptoms in 60%.
Important limitation: This is a confirmed-case series without a workforce denominator, percentages can overlap across sites, and workplace products varied.
Questionnaires, examinations, patch tests, surveillance records and environmental measurements answer different questions. A positive test shows sensitization under test conditions; it does not automatically prove that a workplace material caused current symptoms. A symptom report is not the same as a clinician-confirmed diagnosis, and a referred series cannot estimate risk in the whole occupation.
How to use this evidence in real life
- Write down the exact task, product, material, glove, cleaner, plant, food or equipment involved.
- Record timing: when symptoms begin, where they appear, and what changes away from work.
- Bring labels or safety information to occupational health or a clinician rather than testing workplace chemicals on your own skin.
- Keep required protective procedures in place while alternatives are reviewed.
- Seek prompt care for rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function.
Primary and authoritative sources
- Primary research record: PubMed PMID 26230376
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis overview
- American Academy of Dermatology: eczema skin care
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
Keep the population, denominator, study design and limitations attached to the result. Use the evidence to ask better clinical and exposure-control questions—not to promise a universal outcome.